Contact
Please use this form to send email to PR contact of this press release:
Navrogen Granted Patent to Develop Antibodies That Are Refractory to Immunosuppressive Humoral Immuno-Oncology Factors
TO:
Nicholas C. Nicolaides, President & CEO
Navrogen, Incorporated
+1 610-399-2717